Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Escitalopram vs Reboxetine for Somatic and Visceral Sensitivity in MDD
NCT00209807Phase 4Unknown
- Sponsor
- Vall d'Hebron Research Institute
- Start
- Sep 2005
- Primary completion
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of escitalopram in major depressive disorder (MDD), sponsored by Vall d'Hebron Research Institute. Status: unknown.
02
Drugs
escitalopram
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00209807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00209807.